Protein Information

ID 1012
Name statins
Synonyms STN; statin; statins

Compound Information

ID 1708
Name ACC
CAS 1-aminocyclopropanecarboxylic acid

Reference

PubMed Abstract RScore(About this table)
18345999 Cho L, Hoogwerf B, Huang J, Brennan DM, Hazen SL: Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study. J Womens Health. 2008 May;17(4):515-21.
BACKGROUND: Previous studies have suggested that women with cardiovascular disease may receive less aggressive care than men. Using a large cardiology database from a tertiary referral center, we sought to determine if treatment differences still persist in the current era. METHODS: We analyzed data on 2462 patients who were referred for secondary prevention to the Preventive Cardiology Clinic at The Cleveland Clinic Foundation between 1997 and 2004. The primary objective was to evaluate use of effective secondary preventive therapies, by gender, as outlined in the ACC/AHA guidelines, such as antiplatelet therapy, beta-blockers, statins, and angiotensin-converting enzyme (ACE) inhibitors. Multivariate logistic regression analysis was performed to assess the independent effect of gender on all cause mortality. RESULTS: Women were older (62.2 +/- 11.1 vs. 59.4 +/- 11.0, p < 0.001) and more likely to be hypertensive (68.1% vs. 56.1%, p < 0.001) than men. Overall, women were more likely than men to have higher baseline C-reactive protein (CRP) (6.14 +/- 13.4 vs. 4.9 +/- 10.7, p < 0.001), low-density lipoprotein cholesterol (LDL-C) (135 +/- 66 vs. 116 +/- 46, p < 0.001), high-density lipoprotein cholesterol (HDL-C) (52 +/- 17 vs. 41 +/- 11, p < 0.001), and total cholesterol (238 +/- 98 vs. 202 +/- 65, p < 0.001). Women were less likely to be on antiplatelet therapy (76.6 % vs. 85.0%, p < 0.001) and statins or any lipid-lowering therapy (62.6% vs. 67.1%, p = 0.04) compared with men on presentation. CONCLUSIONS: Even in the current era, women with established cardiovascular disease continue to receive less aggressive care than men. They are less likely to be on aspirin and statin therapy. More aggressive efforts should be made to treat both men and women with standard secondary preventive efforts.
2(0,0,0,2)